Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Illumina to $229 from $224 and keeps a Neutral rating on the shares. The analyst said they reported modest 1Q revenue/EPS upside and reiterated its 2023 outlook. Early NovaSeq X launch commentary was largely constructive, with the company outpacing its initial placements guidance and raising 2023 shipment expectations.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ILMN:
- Illumina reports Q1 non-GAAP EPS 8c, consensus 2c
- Illumina Reports Financial Results for First Quarter of Fiscal Year 2023; Announces Commitment to Accelerate Margin Growth
- Illumina sees FY23 non GAAP EPS $1.25-$1.50, consensus $1.41
- Illumina options imply 5.4% move in share price post-earnings
- Icahn issues letter to Illumina, accuses of ‘attempt to disenfranchise’ holders